Latest filing published 27 Aug 2025 for Ascletis Pharma Inc. - B, €42.7M.
Based on 13 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
WU Judy Hejingdao is a declared insider of Ascletis Pharma Inc. - B, with filings sourced from HKEX. Between 1 August 2018 and 25 August 2025, the trades on record add up to 22 filings.
Both buying and selling appear: 14 purchases worth €6.3M, against 1 sale worth €42.7M. The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2025 alone, the filings show 1 purchase and 1 sale.
In size, the median ticket on the buying side is €399k. Of 13 purchases, 13 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Looking at 13 purchases old enough to measure, the stock rose over the following 90 days in 69% of cases; the median change was +188.0%. They describe history only and say nothing certain about the share price ahead.
Most recently, on 27 August 2025, the filings show an open-market sale worth €42.7M in Ascletis Pharma Inc. - B. The latest purchase dates back some time: it was published 649 days ago, on 13 January 2025. Filings reach the HKEX feed a median of 4 days after the trade. That lag is the time during which only the insider knows about the trade. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 21 declarations